Table 2.
Sensitization of Cancer Cells to Structurally Different Anticancer Drugs Known to Be P-gp Substrates by Saq or Saq-NO Concentrations That Did Not Affect Cancer Cell Viability.
| Cell Line (P-gp Status*) | Anticancer Drug | IC50† (ng/ml) Anticancer Drug | Saq (µM) | IC50 (ng/ml) Anticancer Drug in the Presence of Saq (Fold Sensitization‡) | Saq-NO (µM) | IC50 (ng/ml) Anticancer Drug in the Presence of Saq-NO (Fold Sensitization§) |
| UKF-NB-3 (-) | Vincristine | 0.20 ± 0.08 | 10 | 0.14 ± 0.02 (1.4) | 5 | 0.10 ± 0.04 (2.0) |
| Actinomycin D | 0.19 ± 0.07 | 10 | 0.18 ± 0.06 (1.1) | 5 | 0.16 ± 0.05 (1.2) | |
| Paclitaxel | 1.12 ± 0.35 | 10 | 0.79 ± 0.15 (1.4) | 5 | 0.88 ± 0.20 (1.3) | |
| UKF-NB-3rVCR10 (+) | Vincristine | 40.29 ± 5.07 | 10 | 3.43 ± 0.93¶ (11.8) | 5 | 0.31 ± 0.04¶,# (130.0) |
| Actinomycin D | 6.58 ± 1.43 | 10 | 3.18 ± 1.15¶ (2.1) | 5 | 0.22 ± 0.02¶,# (29.9) | |
| Paclitaxel | 40.86 ± 7.48 | 10 | 12.26 ± 2.23¶ (3.3) | 5 | 3.05 ± 0.34¶,# (13.4) | |
| Rh30 (-) | Vincristine | 0.56 ± 0.15 | 10 | 0.32 ± 0.07 (1.8) | 2.5 | 0.39 ± 0.13 (1.4) |
| Actinomycin D | 0.32 ± 0.10 | 10 | 0.28 ± 0.03 (1.1) | 2.5 | 0.23 ± 0.07 (1.4) | |
| Paclitaxel | 4.48 ± 0.51 | 10 | 3.62 ± 0.65 (1.2) | 2.5 | 3.73 ± 0.64 (1.2) | |
| Rh30rVCR10 (+) | Vincristine | 37.21 ± 6.89 | 10 | 17.36 ± 3.41¶ (2.1) | 5 | 0.21 ± 0.09¶,# (177.2) |
| Actinomycin D | 12.85 ± 2.75 | 10 | 4.81 ± 1.39¶ (2.7) | 5 | 1.49 ± 0.17¶,# (8.6) | |
| Paclitaxel | 90.74 ± 10.91 | 10 | 36.93 ± 7.18¶ (2.5) | 5 | 6.77 ± 1.19¶,# (13.4) |
Values are mean ± SD from three independent experiments.
*
+ = high P-gp expression, - = low P-gp expression.
†
Concentration that decreases cell viability by 50%.
‡
IC50 anticancer drug/IC50 anticancer drug + saq.
§
IC50 anticancer drug/IC50 anticancer drug + saq-NO.
¶
P < .05 relative to anticancer drug alone.
#
P < .05 relative to anticancer drug + saq.